Thus we confirm the hypothesis that RASSF1A plays a role in the cellular response to Taxol and provide proof of principal for the use of epigenetic therapy as strategy to address the problem of Taxol resistance ovarian cancer. The gene discussed is RASSF1; the disease is ovarian carcinoma.